Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial
Rheumatology and Immunology Research · 08.04.2026 · 7 (1) · 41-50
DOI: 10.1515/rir-2026-0016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology and Immunology Research, online erschienen am 30.03.2026. Verfasst von Xiaofeng Zeng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of Xeligekimab (GR1501), a fully human monoclonal antibody against interleukin-17A, in Chinese patients with active axial spondyloarthritis (axSpA) who did not respond or were intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Methods
This phase II, randomized, double-blind, placebo-controlled, multicenter study enrolled 160 patients with active axSpA. Participants were randomized equally to receive placebo or Xeligekimab at 100 mg, 200 mg, or 300 mg subcutaneously every two weeks for 16 weeks, followed by an 8-week follow-up. The primary endpoint was the Assessment of SpondyloArthritis International Society 20 (ASAS20) response at week 16. Secondary endpoints included ASAS40, ASDAS-CRP, BASDAI, BASFI, and patient-reported outcomes. Safety and immunogenicity were evaluated throughout the study.
Results
At week 16, ASAS20 response rates were 52.5% with placebo and 77.5%, 75.0%, and 72.5% with Xeligekimab 100 mg, 200 mg, and 300 mg, respectively. The 100 mg and 200 mg groups showed significant improvement versus placebo ( P < 0.05). Benefits in ASAS40, ASDAS-CRP, and BASDAI were maintained through week 24. Xeligekimab was generally well tolerated, and the overall incidence of adverse events was comparable to placebo. No treatment-emergent anti-drug antibodies were detected.
Conclusion
Xeligekimab at 100 mg and 200 mg achieved meaningful clinical improvement with good tolerability in patients with active axSpA, supporting further clinical evaluation of this therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
- Department of Rheumatology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei, Anhui Province, China.
- Department of Rheumatology and Immunology, The First Hospital of Jilin University, Changchun, Jilin Province, China.
- Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Dong Xu
Zitieren
APA
Zeng, X., Zhang, S., Liu, H., Zhao, Y., Li, X., Jiang, Z., Xue, Y., Kong, N., Sun, L., Liu, S., Fan, X., Hu, J., Shen, L., & Xu, D. (2026). Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial. Rheumatology and Immunology Research, 7(1), 41-50. https://doi.org/10.1515/rir-2026-0016
Vancouver
Zeng X, Zhang S, Liu H, Zhao Y, Li X, Jiang Z, et al. Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial. Rheumatology and Immunology Research. 2026;7(1):41-50. doi:10.1515/rir-2026-0016
BibTeX
@article{Zeng2026,
author = {Zeng, Xiaofeng and Zhang, Shangzhu and Liu, Huaxiang and Zhao, Yi and Li, Xiaomei and Jiang, Zhenyu and Xue, Yu and Kong, Ning and Sun, Lingyun and Liu, Shengyun and Fan, Xiaoyun and Hu, Jiankang and Shen, Liying and Xu, Dong},
title = {Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial},
journal = {Rheumatology and Immunology Research},
year = {2026},
volume = {7},
number = {1},
pages = {41--50},
doi = {10.1515/rir-2026-0016}
}
EUVIMED